Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141105 | 0.90 | TSHR (0.32) | TSHRALDH1A1SLC6A4KMT2ASLC6A2 | |
| SCHEMBL2101604 | 0.88 | TSHR (0.33) | TSHRALDH1A1SLC6A4KMT2ASLC6A2 | |
| SCHEMBL6036795 | 0.85 | ALDH1A1 (0.32) | TSHRALDH1A1SLC6A4KMT2ASLC6A2 | |
| SCHEMBL6036841 | 0.85 | HTT (0.32) | TSHRALDH1A1SLC6A4KMT2ASLC6A2 | |
| SCHEMBL15842572 | 0.82 | NPBWR1 (0.32) | TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL6036882 | 0.80 | TSHR (0.34) | TSHR | |
| SCHEMBL1033574 | 0.80 | GABRA1 (0.39) | TSHRALDH1A1SLC6A2GABRA1GABRB2 | |
| SCHEMBL29393805 | 0.79 | NPBWR1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL139764 | 0.79 | NPBWR1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL11837296 | 0.79 | TSHR (0.34) | TSHRALDH1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169411-B2 | Recording material | SEIKO EPSON CORPORATION (JP) | 2015-10-27 | — | — | US | disclosed |
| US-7500895-B2 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060127563-A1 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2006-06-15 | — | — | US | disclosed |
| US-6974876-B2 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-12-04 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6388094-B1 | FORMING AN AMINOEPOXIDE | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| EP-0855388-B1 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | SEARLE & CO (US) | 2002-03-06 | — | — | EP | disclosed |
| US-5872299-A | Method of preparing intermediates for retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0855388-A2 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998029401-A1 | AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT | G.D. SEARLE & CO. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5583238-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | TSHR 4812/4885ALDH1A1 150/4885SLC6A4 2994/4885 |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | TSHR 4807/4885ALDH1A1 152/4885SLC6A4 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.